TFEB overexpression in excitatory neurons ameliorates amyloid‐β pathology via coordinated enhancement of autophagy‐lysosome and mitochondrial function

The intraneuronal accumulation of amyloid-β (Aβ) is an early pathogenic event in Alzheimer's disease (AD), initiating a pathological cascade that includes synaptic dysfunction, metabolic deficits, and eventual neuronal loss. Transcription factor EB (TFEB), a master regulator of the autophagy-lysosomal pathway (ALP) and mitochondrial homeostasis, represents a promising therapeutic target. However, its efficacy and mechanisms when specifically activated in neurons during the prodromal stage remain unclear. Here, we used an adeno-associated virus (AAV) under the control of the CaMKIIα promoter to achieve excitatory neuron-specific TFEB overexpression in the hippocampal CA1 region of 2 months-old 5×FAD mice. This intervention significantly reduced soluble Aβ levels at 3 months and attenuated amyloid plaque burden, dystrophic neurite formation, and glial activation at 6 months, accompanied by substantial improvements in spatial learning and memory. Mechanistically, transcriptomic and functional analyses revealed that TFEB not only enhanced autophagic flux and lysosomal biogenesis but also promoted the expression of key mitochondrial genes and improved mitochondrial function. In APP695swe-N2a cells, TFEB overexpression increased levels of LC3B-II and LAMP1, enhanced mitochondrial activity and biogenesis (via PGC-1α upregulation), and effectively reduced intracellular Aβ accumulation. Our findings demonstrate that targeted TFEB overexpression in excitatory neurons during early AD pathogenesis initiates a protective cascade by co-activating autophagy-lysosomal clearance and mitochondrial pathways, thereby reducing Aβ accumulation and mitigating downstream pathology. This study highlights the potential of neuron-specific TFEB activation as a cell-type-specific therapeutic approach for early AD intervention. © 2026 The Pathological Society of Great Britain and Ireland.

Authors

Institutions

Publication Details

Journal
The Journal of Pathology
Published
2026-11-17
DOI
https://doi.org/10.1002/path.70153
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

TFEB overexpression in excitatory neurons ameliorates amyloid‐β pathology via coordinated enhancement of autophagy‐lysosome and mitochondrial function

Yi‐Shu Zhang, Yonggang Wang, Jiaxin Cao, Zhenchang Zhang et al.
2 links
The Journal of Pathology
Alzheimer's disease research and treatments
article

TFEB overexpression in excitatory neurons ameliorates amyloid‐β pathology via coordinated enhancement of autophagy‐lysosome and mitochondrial function

Yi‐Shu Zhang, Yonggang Wang, Jiaxin Cao, Zhenchang Zhang, Lipeng Jing, Yuhong Jing, Chen Hai‐Chao, Wang Lei, Yue‐zhang Ma
article en

Abstract

The intraneuronal accumulation of amyloid-β (Aβ) is an early pathogenic event in Alzheimer's disease (AD), initiating a pathological cascade that includes synaptic dysfunction, metabolic deficits, and eventual neuronal loss. Transcription factor EB (TFEB), a master regulator of the autophagy-lysosomal pathway (ALP) and mitochondrial homeostasis, represents a promising therapeutic target. However, its efficacy and mechanisms when specifically activated in neurons during the prodromal stage remain unclear. Here, we used an adeno-associated virus (AAV) under the control of the CaMKIIα promoter to achieve excitatory neuron-specific TFEB overexpression in the hippocampal CA1 region of 2 months-old 5×FAD mice. This intervention significantly reduced soluble Aβ levels at 3 months and attenuated amyloid plaque burden, dystrophic neurite formation, and glial activation at 6 months, accompanied by substantial improvements in spatial learning and memory. Mechanistically, transcriptomic and functional analyses revealed that TFEB not only enhanced autophagic flux and lysosomal biogenesis but also promoted the expression of key mitochondrial genes and improved mitochondrial function. In APP695swe-N2a cells, TFEB overexpression increased levels of LC3B-II and LAMP1, enhanced mitochondrial activity and biogenesis (via PGC-1α upregulation), and effectively reduced intracellular Aβ accumulation. Our findings demonstrate that targeted TFEB overexpression in excitatory neurons during early AD pathogenesis initiates a protective cascade by co-activating autophagy-lysosomal clearance and mitochondrial pathways, thereby reducing Aβ accumulation and mitigating downstream pathology. This study highlights the potential of neuron-specific TFEB activation as a cell-type-specific therapeutic approach for early AD intervention. © 2026 The Pathological Society of Great Britain and Ireland.

The Journal of Pathology
Capital Medical University (CN), Beijing Tian Tan Hospital (CN), Xian Center for Disease Control and Prevention (CN), Lanzhou University Second Hospital (CN), Lanzhou University (CN)
Lanzhou University Second Hospital
Good health and well-being
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon